QL1706 combined with SOX before and after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have adenocarcinoma (a type of cancer) of the stomach or where the stomach meets the esophagus, at a stage where surgery is possible and the tumor is T3 or higher or has spread to lymph nodes (stage N+).
- You must not have had any prior cancer treatment for this diagnosis, such as chemotherapy, radiation, or surgery.
- You need to be between 18 and 75 years old and be in generally good health (able to do daily activities with little help).
- Your blood counts and organ function (kidney, liver, heart) need to be within certain limits, as checked by tests.
- You must agree to use effective birth control during the study and for 4 months after the last dose.
- You cannot have other serious health issues, like active infections, autoimmune diseases, heart problems, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial tests whether giving a combination of immunotherapy (QL1706) and chemotherapy before surgery helps shrink diffuse-type stomach cancer more than chemotherapy alone. The goal is to improve the chance of successful surgery and better long-term outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
Hear when a new Gastric Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.